Faricimab

SENSORY ORGANS

Key facts

Faricimab is a drug catalogued in DrugCentral. It was first approved by the FDA in 2022. DrugCentral lists 2 molecular targets, including VEGFA and ANGPT2. Recorded indications include Exudative age-related macular degeneration and Macular edema due to diabetes mellitus.

• Molecular targets: VEGFA and ANGPT2 (2 listed in DrugCentral).
• Indications: Exudative age-related macular degeneration and Macular edema due to diabetes mellitus.
• ATC code: S01LA09 (Antineovascularisation agents).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Exudative age-related macular degeneration
• Macular edema due to diabetes mellitus

Contraindications (2)

• Ocular or periocular infection
• Uveitis

Mechanism & targets

Molecular targets (2)

Target	Gene	Action	Activity
Vascular endothelial growth factor A	VEGFA	other	Kd 8.76
Angiopoietin-2	ANGPT2	other	Kd 7.70

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2022-09-15	EMA	—	ROCHE REGISTRATION GMBH
2022-03-28	PMDA	—	Chugai Pharmaceutical Co., Ltd
2022-01-28	FDA	—	GENENTECH INC

ATC classification

ATC code	Therapeutic hierarchy
S01LA09	SENSORY ORGANS › OPHTHALMOLOGICALS › OCULAR VASCULAR DISORDER AGENTS › Antineovascularisation agents

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Retinal thickening	5569.5
Optical coherence tomography abnormal	3038.8
Eye inflammation	909.9
Visual acuity tests abnormal	879.7
Vitritis	724.7
Off label use	678.5
Uveitis	645.8
No adverse event	633.5
Visual impairment	596.1
Endophthalmitis	591.5
Iridocyclitis	581.3
Visual acuity reduced	449.4

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 1607793-29-2
• InChIKey: —
• PubChem CID: 91827367

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Faricimab used for?

DrugCentral lists the following indications for Faricimab: Exudative age-related macular degeneration and Macular edema due to diabetes mellitus.

How does Faricimab work?

Its molecular targets in DrugCentral include VEGFA and ANGPT2.

When was Faricimab first approved?

Faricimab was first approved by the FDA in 2022.

Sources

• DrugCentral drug card 5515 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL4297750 — compound record and bioactivity
• PubChem CID 91827367 — chemical identifiers
• DrugBank DB15303 — drug record
• FDA UNII QC4F7FKK7I — substance identity
• DailyMed: FDA labels for Faricimab — current prescribing information (label search)
• UniProt P15692 (VEGFA) — target protein
• UniProt O15123 (ANGPT2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.